Alzheimer’s Research Papers ~ March 2002 ~ Beta Amyloid Blog

2002: March: Alzheimer’s Research Papers 

Silva JL, Oliveira AC, Gomes AM, Lima LM, Mohana-Borges R, Pacheco AB, Foguel D. Pressure induces folding intermediates that are crucial for protein-DNA recognition and virus assembly. Biochim Biophys Acta. 2002 Mar 25;1595(1-2):250-65.

Mazur-Kolecka B, Frackowiak J, Kowal D, Krzeslowska J, Dickson D. Oxidative protein damage in cells engaged in beta-amyloidosis is related to apoE genotype. Neuroreport. 2002 Mar 25;13(4):465-8.

Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC. Diet-induced hypercholesterolemia enhances brain Abeta accumulation in transgenic mice. Neuroreport. 2002 Mar 25;13(4):455-9.

Hayashi H, Igbavboa U, Hamanaka H, Kobayashi M, Fujita SC, Wood WG, Yanagisawa K. Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. Neuroreport. 2002 Mar 25;13(4):383-6.

  

Demattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002 Mar 22;295(5563):2264-7. ,

    

Kim SH, Krapfenbauer K, Cheon MS, Fountoulakis M, Cairns NJ, Lubec G. Human brain cytosolic histamine-N-methyltransferase is decreased in Down syndrome and increased in Pick's disease. Neurosci Lett. 2002 Mar 22;321(3):169-72.

FitzGerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol. 2002 Mar 21;89(6A):26D-32D.

Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, Silman I. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry. 2002 Mar 19;41(11):3555-64.

Alves da Costa C, Paitel E, Mattson MP, Amson R, Telerman A, Ancolio K, Checler F. Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons. Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):4043-8.

Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol. 2002 Mar 18;156(6):1051-63.

 

Lam W. Pharmacological treatment of cognitive deficits in Alzheimer's disease. Med J Aust. 2002 Mar 18;176(6):297; discussion 297-8.

Gibson GE, Zhang H, Xu H, Park LC, Jeitner TM. Oxidative stress increases internal calcium stores and reduces a key mitochondrial enzyme. Biochim Biophys Acta. 2002 Mar 16;1586(2):177-89.

Murphy MP, Uljon SN, Golde TE, Wang R. FAD-linked mutations in presenilin 1 alter the length of Abeta peptides derived from betaAPP transmembrane domain mutants. Biochim Biophys Acta. 2002 Mar 16;1586(2):199-209.

Kanski J, Varadarajan S, Aksenova M, Butterfield DA. Role of glycine-33 and methionine-35 in Alzheimer's amyloid beta-peptide 1-42-associated oxidative stress and neurotoxicity. Biochim Biophys Acta. 2002 Mar 16;1586(2):190-8.

Kim KS, Choi SY, Kwon HY, Won MH, Kang TC, Kang JH. Aggregation of alpha-synuclein induced by the Cu,Zn-superoxide dismutase and hydrogen peroxide system. Free Radic Biol Med. 2002 Mar 15;32(6):544-50.

 

Nilsen J, Chen S, Brinton RD. Dual action of estrogen on glutamate-induced calcium signaling: mechanisms requiring interaction between estrogen receptors and src/mitogen activated protein kinase pathway. Brain Res. 2002 Mar 15;930(1-2):216-34.

Kadish I, Pradier L, van Groen T. Transgenic mice expressing the human presenilin 1 gene demonstrate enhanced hippocampal reorganization following entorhinal cortex lesions. Brain Res Bull. 2002 Mar 15;57(5):587-94.

Panayi AE, Spyrou NM, Iversen BS, White MA, Part P. Determination of cadmium and zinc in Alzheimer's brain tissue using inductively coupled plasma mass spectrometry. J Neurol Sci. 2002 Mar 15;195(1):1-10.

Ferrer I, Lizcano JM, Hernández M, Unzeta M. Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurosci Lett. 2002 Mar 15;321(1-2):21-4.

Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci. 2002 Mar 15;22(6):2246-54.

    

Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol. 2002 Mar 15;317(1):73-83.

Sun X, Sato S, Murayama O, Murayama M, Park JM, Yamaguchi H, Takashima A. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett. 2002 Mar 15;321(1-2):61-4.

Kim MS, Sung MJ, Seo SB, Yoo SJ, Lim WK, Kim HM. Water-soluble chitosan inhibits the production of pro-inflammatory cytokine in human astrocytoma cells activated by amyloid beta peptide and interleukin-1beta. Neurosci Lett. 2002 Mar 15;321(1-2):105-9.

Montine KS, Montine TJ, Morrow JD, Frei B, Milatovic D, Eckenstein F, Quinn JF. Mouse cerebral prostaglandins, but not oxidative damage, change with age and are responsive to indomethacin treatment. Brain Res. 2002 Mar 15;930(1-2):75-82.

Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002 Mar 15;155(6):487-95.

Martinez A, Alonso M, Castro A, Pérez C, Moreno FJ. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem. 2002 Mar 14;45(6):1292-9.

Liedholm H, Linné AB. ["NSAID preparations prevent Alzheimer disease"--a treacherous headline!] Lakartidningen. 2002 Mar 14;99(11):1240.

Rank KB, Pauley AM, Bhattacharya K, Wang Z, Evans DB, Fleck TJ, Johnston JA, Sharma SK. Direct interaction of soluble human recombinant tau protein with Abeta 1-42 results in tau aggregation and hyperphosphorylation by tau protein kinase II. FEBS Lett. 2002 Mar 13;514(2-3):263-8.

Campbell WA, Iskandar MK, Reed ML, Xia W. Endoproteolysis of presenilin in vitro: inhibition by gamma-secretase inhibitors. Biochemistry. 2002 Mar 12;41(10):3372-9.

Chan D, Fox N, Rossor M. Differing patterns of temporal atrophy in Alzheimer's disease and semantic dementia. Neurology. 2002 Mar 12;58(5):838.

Jack CR, Dickson DW, Parisi JE, Xu YC, Cha RH, O'Brien PC, Edland SD, Smith GE, Boeve BF, Tangalos EG, Kokmen E, Petersen RC. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002 Mar 12;58(5):750-7.

Øksengård AR, Haakonsen M, Dullerud R, Babovic A, Laake K, Engedal K. [In Process Citation] Tidsskr Nor Laegeforen. 2002 Mar 10;122(7):710-4.

Lopez MF, Melov S. Applied proteomics: mitochondrial proteins and effect on function. Circ Res. 2002 Mar 8;90(4):380-9.

Hu YY, He SS, Wang XC, Duan QH, Khatoon S, Iqbal K, Grundke-Iqbal I, Wang JZ. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett. 2002 Mar 8;320(3):156-60. ,

Myers A, Wavrant De-Vrieze F, Holmans P, Hamshere M, Crook R, Compton D, Marshall H, Meyer D, Shears S, Booth J, Ramic D, Knowles H, Morris JC, Williams N, Norton N, Abraham R, Kehoe P, Williams H, Rudrasingham V, Rice F, Giles P, Tunstall N, Jones L, Lovestone S, Williams J, Owen MJ, Hardy J, Goate A. Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet. 2002 Mar 8;114(2):235-44.

Nguyen KV, Gendrault JL, Wolff CM. Poly-L-lysine dissolves fibrillar aggregation of the Alzheimer beta-amyloid peptide in vitro. Biochem Biophys Res Commun. 2002 Mar 8;291(4):764-8.

 

Patzke H, Tsai LH. Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29. J Biol Chem. 2002 Mar 8;277(10):8054-60.

Moldoveanu T, Hosfield CM, Lim D, Elce JS, Jia Z, Davies PL. A Ca(2+) switch aligns the active site of calpain. Cell. 2002 Mar 8;108(5):649-60.

Yaar M, Zhai S, Fine RE, Eisenhauer PB, Arble BL, Stewart KB, Gilchrest BA. Amyloid beta binds trimers as well as monomers of the 75-kDa neurotrophin receptor and activates receptor signaling. J Biol Chem. 2002 Mar 8;277(10):7720-5.

Gauthier S. Advances in the pharmacotherapy of Alzheimer's disease. CMAJ. 2002 Mar 5;166(5):616-23.

Wang W, Hecht MH. Rationally designed mutations convert de novo amyloid-like fibrils into monomeric beta-sheet proteins. Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2760-5.

Dvir H, Wong DM, Harel M, Barril X, Orozco M, Luque FJ, Muñoz-Torrero D, Camps P, Rosenberry TL, Silman I, Sussman JL. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates. Biochemistry. 2002 Mar 5;41(9):2970-81.

Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, Wolfe MS. Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2720-5.

    

Brower V. Harnessing the immune system to battle Alzheimer's: Some of the most promising approaches to fight Alzheimer's disease aim to develop vaccines. EMBO Rep. 2002 Mar;3(3):207-9.

Trudeau VL, Chiu S, Kennedy SW, Brooks RJ. Octylphenol (OP) Alters the Expression of Members of the Amyloid Protein Family in the Hypothalamus of the Snapping Turtle, Chelydra serpentina serpentina. Environ Health Perspect. 2002 Mar;110(3):269-75.

Matsuda H, Kitayama N, Ohnishi T, Asada T, Nakano S, Sakamoto S, Imabayashi E, Katoh A. Longitudinal evaluation of both morphologic and functional changes in the same individuals with Alzheimer's disease. J Nucl Med. 2002 Mar;43(3):304-11.

Westbury C, Bub D, Chertkow H. Distinct neurolinguistic symptom clusters in Alzheimer's-type dementia and primary progressive aphasia. Brain Cogn. 2002 Mar-Apr;48(2-3):611-7.

Forbes KE, Venneri A, Shanks MF. Distinct patterns of spontaneous speech deterioration: an early predictor of Alzheimer's disease. Brain Cogn. 2002 Mar-Apr;48(2-3):356-61.

Umahara T, Tsuchiya K, Ikeda K, Kanaya K, Iwamoto T, Takasaki M, Mukai K, Shibata N, Kato S. Demonstration and distribution of tau-positive glial coiled body-like structures in white matter and white matter threads in early onset Alzheimer's disease. Neuropathology. 2002 Mar;22(1):9-12.

Iseki E, Tsunoda S, Suzuki K, Takayama N, Akatsu H, Yamamoto T, Kosaka K. Regional quantitative analysis of NFT in brains of non-demented elderly persons: comparisons with findings in brains of late-onset Alzheimer's disease and limbic NFT dementia. Neuropathology. 2002 Mar;22(1):34-9.

Ogawa O, Perry G, Smith MA. The "Down's" side of mitochondria. Dev Cell. 2002 Mar;2(3):255-6.

Wang J, Wang X, Liu R, Wang Q, Grundke-Iqbal I, Iqbal K. In vitro analysis of tau phosphorylation sites and its biological activity. Chin Med Sci J. 2002 Mar;17(1):13-6.

Frodl T, Hampel H, Juckel G, Bürger K, Padberg F, Engel RR, Möller HJ, Hegerl U. Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. Psychophysiology. 2002 Mar;39(2):175-81. ,

Maurizi CP. Postencephalitic Parkinson's disease, amyotrophic lateral sclerosis on Guam and influenza revisited: focusing on neurofibrillary tangles and the trail of tau. Med Hypotheses. 2002 Mar;58(3):198-202.

Auchterlonie S, Phillips NA, Chertkow H. Behavioral and electrical brain measures of semantic priming in patients with Alzheimer's disease: implications for access failure versus deterioration hypotheses. Brain Cogn. 2002 Mar-Apr;48(2-3):264-7.

Kaufmann L, Montanes P, Jacquier M, Matallana D, Eibl G, Delazer M. About the relationship between basic numerical processing and arithmetics in early Alzheimer's disease--a follow-up study. Brain Cogn. 2002 Mar-Apr;48(2-3):398-405.

Hatters DM, Howlett GJ. The structural basis for amyloid formation by plasma apolipoproteins: a review. Eur Biophys J. 2002 Mar;31(1):2-8.

Behl C, Moosmann B. Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as neuroprotective compounds. Biol Chem. 2002 Mar-Apr;383(3-4):521-36.

Dudkin KN, Chueva IV, Makarov FN, Beach TG, Roher A. Impaired processes of working memory in the monkey model of Alzheimer's disease. Dokl Biol Sci. 2002 Mar-Apr;383(1-6):106-8.

Nakamura K. Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. CNS Drug Rev. 2002 Spring;8(1):70-89.

Trabace L, Cassano T, Loverre A, Steardo L, Cuomo V. CHF2819: Pharmacological Profile of a Novel Acetylcholinesterase Inhibitor. CNS Drug Rev. 2002 Spring;8(1):53-69.

D'Andrea MR, Nagele RG. MAP-2 immunolabeling can distinguish diffuse from dense-core amyloid plaques in brains with Alzheimer's disease. Biotech Histochem. 2002 Mar;77(2):95-103.

 

Vollans AK, Shukla C, Bridges LR. Immunohistochemical characterization and quantification of Marinesco bodies in Alzheimer's and Parkinson's diseases. Neuropathol Appl Neurobiol. 2002 Mar;28(2):166.

Duff K, McCaffrey RJ, Solomon GS. The pocket smell test: successfully discriminating probable Alzheimer's dementia from vascular dementia and major depression. J Neuropsychiatry Clin Neurosci. 2002 Spring;14(2):197-201.

Delibas N, Ozcankaya R, Altuntas I. Clinical importance of erythrocyte malondialdehyde levels as a marker for cognitive deterioration in patients with dementia of Alzheimer type: a repeated study in 5-year interval. Clin Biochem. 2002 Mar;35(2):137-41.

Bayer AU, Ferrari F. Severe progression of glaucomatous optic neuropathy in patients with Alzheimer's disease. Eye. 2002 Mar;16(2):209-12.

Whittaker KW, Burdon MA, Shah P. Visual field loss and Alzheimer's disease. Eye. 2002 Mar;16(2):206-8.

Ma Q, Dudas B, Hejna M, Cornelli U, Lee JM, Lorens S, Mervis R, Hanin I, Fareed J. The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3. Thromb Res. 2002 Mar 1;105(5):447-53.

Wisniewski K, Carr H. (S)-3,5-DHPG: A Review. CNS Drug Rev. 2002 Spring;8(1):101-16.

Ripich DN, Fritsch T, Ziol E. Everyday problem solving in African Americans and European Americans with Alzheimer's disease: an exploratory study. Int Psychogeriatr. 2002 Mar;14(1):83-95.

Mastwyk M, Ritchie CW, LoGiudice D, Sullivan KA, Macfarlane S. Carer impressions of participation in Alzheimer's disease clinical trials: what are their hopes? And is it worth it? Int Psychogeriatr. 2002 Mar;14(1):39-45.

Tabet N, Mantle D, Walker Z, Orrell M. Endogenous antioxidant activities in relation to concurrent vitamins A, C, and E intake in dementia. Int Psychogeriatr. 2002 Mar;14(1):7-15.

Bottino CM, Castro CC, Gomes RL, Buchpiguel CA, Marchetti RL, Neto MR. Volumetric MRI measurements can differentiate Alzheimer's disease, mild cognitive impairment, and normal aging. Int Psychogeriatr. 2002 Mar;14(1):59-72.

Hake AM. The treatment of Alzheimer's disease: the approach from a clinical specialist in the trenches. Semin Neurol. 2002 Mar;22(1):71-4.

Geldmacher DS. Cost-effective recognition and diagnosis of dementia. Semin Neurol. 2002 Mar;22(1):63-70.

Curtis D, North BV, Sham PC. Extension of conditional model-free likelihood-based linkage analysis to additive and other models. Ann Hum Genet. 2002 Mar;66(Pt 2):157-67.

Yesavage JA, Taylor JL, Kraemer H, Noda A, Friedman L, Tinklenberg JR. Sleep/Wake cycle disturbance in Alzheimer's disease: how much is due to an inherent trait? Int Psychogeriatr. 2002 Mar;14(1):73-81.

Singhal MK. Early diagnosis of Alzheimer's disease. Indian J Exp Biol. 2002 Mar;40(3):373.

Danysz W, Parsons CG. Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res. 2002 Mar;4(2):119-26.

Barrow CJ. Advances in the Development of Abeta-Related Therapeutic Strategies for Alzheimer's Disease. Drug News Perspect. 2002 Mar;15(2):102-109.

Gallassi R, Morreale A, Di Sarro R, Lorusso S. Value of clinical data and neuropsychological measures in probable Alzheimer's disease. Arch Gerontol Geriatr. 2002 Mar-Apr;34(2):123-34.

Woodruff-Pak DS, Gould TJ. Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia. Behav Cogn Neurosci Rev. 2002 Mar;1(1):5-20.

Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med. 2002 Mar 1;8(3):126-32.

Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 2002 Mar;26(3):325-39.

Nakayama J, Yoshizawa T, Yamamoto N, Arinami T. Mutation analysis of the calpastatin gene (CAST) in patients with Alzheimer's disease. Neurosci Lett. 2002 Mar 1;320(1-2):77-80. ,

Doraiswamy PM, Leon J, Cummings JL, Marin D, Neumann PJ. Prevalence and impact of medical comorbidity in Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2002 Mar;57(3):M173-7.

Pérez M, Hernández F, Gómez-Ramos A, Smith M, Perry G, Avila J. Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur J Biochem. 2002 Mar;269(5):1484-9.

Diehl J, Kurz A. [Vascular dementias] Fortschr Neurol Psychiatr. 2002 Mar;70(3):145-54.

Janka Z, Juhász A, Rimanóczy A, Boda K, Márki-Zay J, Palotás M, Kuk I, Zöllei M, Jakab K, Kálmán J. Alpha2-macroglobulin exon 24 (Val-1000-Ile) polymorphism is not associated with late-onset sporadic Alzheimer's dementia in the Hungarian population. Psychiatr Genet. 2002 Mar;12(1):49-54. ,

Cohen GD. Creative interventions for Alzheimer's disease. Familiar activities, videos can help patients cope with memory loss. Geriatrics. 2002 Mar;57(3):62, 65.

Steinhilb ML, Turner RS, Gaut JR. ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways. J Neurochem. 2002 Mar;80(6):1019-28.

Budson AE, Michalska KJ, Rentz DM, Joubert CC, Daffner KR, Schacter DL, Sperling RA. Use of a false recognition paradigm in an Alzheimer's disease clinical trial: a pilot study. Am J Alzheimers Dis Other Demen. 2002 Mar-Apr;17(2):93-100.

Allen B. Multimodal behavior management for people with dementia. Am J Alzheimers Dis Other Demen. 2002 Mar-Apr;17(2):89-91.

Okazawa H, Estus S. The JNK/c-Jun cascade and Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2002 Mar-Apr;17(2):79-88.

Sanderson M, Wang J, Davis DR, Lane MJ, Cornman CB, Fadden MK. Co-morbidity associated with dementia. Am J Alzheimers Dis Other Demen. 2002 Mar-Apr;17(2):73-8.

Stolley JM, Reed D, Buckwalter KC. Caregiving appraisal and interventions based on the progressively lowered stress threshold model. Am J Alzheimers Dis Other Demen. 2002 Mar-Apr;17(2):110-20.

Kane MN. Awareness of ageism, motivation, and countertransference in the care of elders with Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2002 Mar-Apr;17(2):101-9.

Birmingham K, Frantz S. Set back to Alzheimer vaccine studies. Nat Med. 2002 Mar;8(3):199-200.

Thomas T, Bhavnani BR, Thomas P. Inhibition of human LDL oxidation by the neuroprotective drug l-deprenyl. Neurol Res. 2002 Mar;24(2):169-73.

Moroz OV, Antson AA, Dodson EJ, Burrell HJ, Grist SJ, Lloyd RM, Maitland NJ, Dodson GG, Wilson KS, Lukanidin E, Bronstein IB. The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr D Biol Crystallogr. 2002 Mar;58(Pt 3):407-13.

Stevens T, Livingston G, Kitchen G, Manela M, Walker Z, Katona C. Islington study of dementia subtypes in the community. Br J Psychiatry. 2002 Mar;180:270-6.

Riemenschneider M, Schmolke M, Lautenschlager N, Vanderstichele H, Vanmechelen E, Guder WG, Kurz A. Association of CSF apolipoprotein E, Abeta42 and cognition in Alzheimer's disease. Neurobiol Aging. 2002 Mar-Apr;23(2):205-11.

Tarkowski E, Issa R, Sjögren M, Wallin A, Blennow K, Tarkowski A, Kumar P. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging. 2002 Mar-Apr;23(2):237-43. ,

Wang HY, D'Andrea MR, Nagele RG. Cerebellar diffuse amyloid plaques are derived from dendritic Abeta42 accumulations in Purkinje cells. Neurobiol Aging. 2002 Mar-Apr;23(2):213-23.

Kéri S, Janka Z, Benedek G, Aszalós P, Szatmáry B, Szirtes G, Lörincz A. Categories, prototypes and memory systems in Alzheimer's disease. Trends Cogn Sci. 2002 Mar 1;6(3):132-136.

Hashimoto Y, Niikura T, Ito Y, Kita Y, Terashita K, Nishimoto I. Neurotoxic mechanisms by Alzheimer's disease-linked N141I mutant presenilin 2. J Pharmacol Exp Ther. 2002 Mar;300(3):736-45.

Wingard EM, Barrett AM, Crucian GP, Doty L, Heilman KM. The Gerstmann syndrome in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):403-5.

Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002 Mar 1;72(3):310-4.

Wijk H, Berg S, Bergman B, Hanson AB, Sivik L, Steen B. Colour perception among the very elderly related to visual and cognitive function. Scand J Caring Sci. 2002 Mar;16(1):91-102.

Visser PJ, Verhey FR, Scheltens P, Cruts M, Ponds RW, Van Broeckhoven CL, Jolles J. Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects. J Neurol. 2002 Mar;249(3):312-9.

Siao CJ, Tsirka SE. Extracellular proteases and neuronal cell death. Cell Mol Biol (Noisy-le-grand). 2002 Mar;48(2):151-61.

Esler WP, Marshall JR, Stimson ER, Ghilardi JR, Vinters HV, Mantyh PW, Maggio JE. Apolipoprotein E affects amyloid formation but not amyloid growth in vitro: mechanistic implications for apoE4 enhanced amyloid burden and risk for Alzheimer's disease. Amyloid. 2002 Mar 1;9(1):1-12.

Balcar VJ. Molecular pharmacology of the Na+-dependent transport of acidic amino acids in the mammalian central nervous system. Biol Pharm Bull. 2002 Mar;25(3):291-301.

Chitsey AM, Haight BK, Jones MM. Snoezelen: a multisensory environmental intervention. J Gerontol Nurs. 2002 Mar;28(3):41-9.

Lopes MA, Bottino CM. [Prevalence of dementia in several regions of the world: analysis of epidemiologic studies from 1994 to 2000] Arq Neuropsiquiatr. 2002 Mar;60(1):61-9.

Pontikis C, Hudson L, Lantos PL, Rezaie P. A quantitative analysis of cellular prion protein (PrPc) expression in Alzheimer's disease (AD), diffuse Lewy body disease (DLBD) and in normal brain. Neuropathol Appl Neurobiol. 2002 Mar;28(2):166-167.

Shukla C, Plant LD, Henderson Z, Bridges LR, Pearson HA. Differential effects of antioxidants on amyloid beta- and H2O2-induced cell death in the SHSY-5Y neuronal cell-line. Neuropathol Appl Neurobiol. 2002 Mar;28(2):169.

Nishimura T. [Will Alzheimer's disease be conquered in the 21st century?] Nippon Ronen Igakkai Zasshi. 2002 Mar;39(2):168-9.

Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol. 2002 Mar-Apr;25(2):107-10.

Porter RJ, Marshall EF, O'Brien JT. Effects of rapid tryptophan depletion on salivary and plasma cortisol in Alzheimer's disease and the healthy elderly. J Psychopharmacol. 2002 Mar;16(1):73-8.

Liu CY, Hong CJ, Liu TY, Lin KN, Wang PN, Chi CW, Chuang YY, Liu HC. Lack of association between the apolipoprotein E genotype and depression in Alzheimer's disease. J Geriatr Psychiatry Neurol. 2002 Spring;15(1):20-3.

Murtha S, Cismaru R, Waechter R, Chertkow H. Increased variability accompanies frontal lobe damage in dementia. J Int Neuropsychol Soc. 2002 Mar;8(3):360-72.

Säljö A, Bao F, Shi J, Hamberger A, Hansson HA, Haglid KG. Expression of c-Fos and c-Myc and deposition of beta-APP in neurons in the adult rat brain as a result of exposure to short-lasting impulse noise. J Neurotrauma. 2002 Mar;19(3):379-85.

Pak J, Green J, Heifets B, Pak M, Woodruff-Pak D. Nefiracetam ameliorates associative learning impairment in the scopolamine-injected older rabbit. Med Sci Monit. 2002 Mar;8(4):BR105-12.

Barber R, McKeith I, Ballard C, O'Brien J. Volumetric MRI study of the caudate nucleus in patients with dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):406-7.

 

Luckmann R. Donepezil improved the clinical state and quality of life in moderate-to-severe Alzheimer disease. ACP J Club. 2002 Mar-Apr;136(2):59.

Oda M, Morino H, Maruyama H, Terasawa H, Izumi Y, Torii T, Sasaki K, Nakamura S, Kawakami H. Dinucleotide repeat polymorphisms in the neprilysin gene are not associated with sporadic Alzheimer's disease. Neurosci Lett. 2002 Mar 1;320(1-2):105-7. ,

 

Mattila P, Togo T, Dickson DW. The subthalamic nucleus has neurofibrillary tangles in argyrophilic grain disease and advanced Alzheimer's disease. Neurosci Lett. 2002 Mar 1;320(1-2):81-5.

Togo T, Akiyama H, Iseki E, Kondo H, Ikeda K, Kato M, Oda T, Tsuchiya K, Kosaka K. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol. 2002 Mar;124(1-2):83-92.

Morley JE, Farr SA, Kumar VB, Banks WA. Alzheimer's disease through the eye of a mouse. Acceptance lecture for the 2001 Gayle A. Olson and Richard D. Olson prize. Peptides. 2002 Mar;23(3):589-99.

Yanagisawa K. [Pathological implications of GM1 ganglioside-bound amyloid beta-protein in Alzheimer's disease] Tanpakushitsu Kakusan Koso. 2002 Mar;47(4 Suppl):344-50.

Dysken M, Kuskowski M, Love S, Ondansetron Study Group. Ondansetron in the treatment of cognitive decline in Alzheimer dementia. Am J Geriatr Psychiatry. 2002 Mar-Apr;10(2):212-5.

Kim SY, Karlawish JH, Caine ED. Current state of research on decision-making competence of cognitively impaired elderly persons. Am J Geriatr Psychiatry. 2002 Mar-Apr;10(2):151-65.

Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry. 2002 Mar-Apr;10(2):129-41.

Mahadeva R, Dafforn TR, Carrell RW, Lomas DA. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis. J Biol Chem. 2002 Mar 1;277(9):6771-4.

Ballerini S, Bellincampi L, Bernardini S, Casciani S, Motti C, Cortese C, Federici G. Apolipoprotein E genotyping: a comparative study between restriction endonuclease mapping and allelic discrimination with the LightCycler. Clin Chim Acta. 2002 Mar;317(1-2):71-6.

Rosenblum WI. Structure and location of amyloid beta peptide chains and arrays in Alzheimer's disease: new findings require reevaluation of the amyloid hypothesis and of tests of the hypothesis. Neurobiol Aging. 2002 Mar-Apr;23(2):225-30.

Lovell MA, Robertson JD, Buchholz BA, Xie C, Markesbery WR. Use of bomb pulse carbon-14 to age senile plaques and neurofibrillary tangles in Alzheimer's disease. Neurobiol Aging. 2002 Mar-Apr;23(2):179-86.

 

Ghebremedhin E, Thal DR, Schultz C, Braak H. Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains. Neurosci Lett. 2002 Mar 1;320(1-2):25-8.

Bush A. Response: ‘…and C is for Clioquinol’ – the AßCs of Alzheimer's disease. Trends Neurosci. 2002 Mar 1;25(3):123-124.

Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H, Seki T, Hirai H, Chiba H, Itoh M, Sasaki H. Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease. Am J Psychiatry. 2002 Mar;159(3):474-6. ,

Arthur D, Levin ED. Chronic inhibition of alpha4beta2 nicotinic receptors in the ventral hippocampus of rats: impacts on memory and nicotine response. Psychopharmacology (Berl). 2002 Mar;160(2):140-5.

Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002 Mar 1;22(5):1858-67. ,

Kabani NJ, Sled JG, Chertkow H. Magnetization transfer ratio in mild cognitive impairment and dementia of Alzheimer's type. Neuroimage. 2002 Mar;15(3):604-10.

Parsian A, Racette B, Goldsmith LJ, Perlmutter JS. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics. 2002 Mar;79(3):458-61.

Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, Greig NH. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002 Mar;300(3):958-66.

Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, Haughey N, Lee J, Evans M, Mattson MP. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci. 2002 Mar 1;22(5):1752-62.

Cummings BJ, Mason AJ, Kim RC, Sheu PC, Anderson AJ. Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging. Neurobiol Aging. 2002 Mar-Apr;23(2):161-70.

Melov S. '...and C is for Clioquinol' - the AbetaCs of Alzheimer's disease. Trends Neurosci. 2002 Mar;25(3):121-3; discussion 123-4.

Gates GA, Beiser A, Rees TS, D'Agostino RB, Wolf PA. Central auditory dysfunction may precede the onset of clinical dementia in people with probable Alzheimer's disease. J Am Geriatr Soc. 2002 Mar;50(3):482-8.

Briani C, Ruggero S, Naccarato M, Cagnin A, Ricchieri GL, Pasqui L, Pizzolato G, Battistin L. Combined analysis of CSF betaA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data. J Neural Transm. 2002 Mar;109(3):393-8. ,

Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm. 2002 Mar 1;109(3):341-60.

Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm. 2002 Mar;109(3):329-39.

Karlström H, Bergman A, Lendahl U, Näslund J, Lundkvist J. A sensitive and quantitative assay for measuring cleavage of presenilin substrates. J Biol Chem. 2002 Mar 1;277(9):6763-6.

Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, Reynolds CF, Rovner BW, Steffens DC, Tariot PN, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002 Mar-Apr;10(2):125-8.

Langbart C. Diagnosing and treating Alzheimer's disease: a practitioner's overview. J Am Acad Nurse Pract. 2002 Mar;14(3):103-9; quiz 110-2.

Hill JW, Futterman R, Mastey V, Fillit H. The effect of donepezil therapy on health costs in a Medicare managed care plan. Manag Care Interface. 2002 Mar;15(3):63-70.

Mizrahi EH, Jacobsen DW, Friedland RP. Plasma homocysteine: a new risk factor for Alzheimer's disease? Isr Med Assoc J. 2002 Mar;4(3):187-90.

Werth E, Savaskan E, Knoblauch V, Gasio PF, van SE, Hock C, Wirz-Justice A. Decline in long-term circadian rest-activity cycle organization in a patient with dementia. J Geriatr Psychiatry Neurol. 2002 Spring;15(1):55-9.

Harwood DG, Sultzer DL. "Life is not worth living": hopelessness in Alzheimer's disease. J Geriatr Psychiatry Neurol. 2002 Spring;15(1):38-43.

Sweet RA, Kamboh MI, Wisniewski SR, Lopez OL, Klunk WE, Kaufer DI, DeKosky ST. Apolipoprotein E andalpha-1-antichymotrypsin genotypes do not predict time to psychosis in Alzheimer's disease. J Geriatr Psychiatry Neurol. 2002 Spring;15(1):24-30.

McPherson S, Fairbanks L, Tiken S, Cummings JL, Back-Madruga C. Apathy and executive function in Alzheimer's disease. J Int Neuropsychol Soc. 2002 Mar;8(3):373-81.

Fischer F, Molinari M, Bodendorf U, Paganetti P. The disulphide bonds in the catalytic domain of BACE are critical but not essential for amyloid precursor protein processing activity. J Neurochem. 2002 Mar;80(6):1079-88.

Heinze M, Andreae D, Grohmann R. Rivastigmin and impaired motor function. Pharmacopsychiatry. 2002 Mar;35(2):79-80.

Liang Z, Valla J, Sefidvash-Hockley S, Rogers J, Li R. Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer's disease patients. J Neurochem. 2002 Mar;80(5):807-14.

Bodendorf U, Danner S, Fischer F, Stefani M, Sturchler-Pierrat C, Wiederhold KH, Staufenbiel M, Paganetti P. Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J Neurochem. 2002 Mar;80(5):799-806.

Reiriz J, Holm PC, Alberch J, Arenas E. BMP-2 and cAMP elevation confer locus coeruleus neurons responsiveness to multiple neurotrophic factors. J Neurobiol. 2002 Mar;50(4):291-304.

Williamson KS, Gabbita SP, Mou S, West M, Pye QN, Markesbery WR, Cooney RV, Grammas P, Reimann-Philipp U, Floyd RA, Hensley K. The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide. 2002 Mar 1;6(2):221-7.

Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, Nunomura A, Castellani RJ, Perry G, Smith MA, Itoyama Y. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis. 2002 Mar;9(2):244-8.

Kim do H, Payne ME, Levy RM, MacFall JR, Steffens DC. APOE genotype and hippocampal volume change in geriatric depression. Biol Psychiatry. 2002 Mar 1;51(5):426-9.

Sasaki K, Doh-ura K, Ironside JW, Iwaki T. Increased clusterin (apolipoprotein J) expression in human and mouse brains infected with transmissible spongiform encephalopathies. Acta Neuropathol (Berl). 2002 Mar;103(3):199-208.

Marshall JR, Stimson ER, Ghilardi JR, Vinters HV, Mantyh PW, Maggio JE. Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo. Bioconjug Chem. 2002 Mar-Apr;13(2):276-84.

Smyth PG, Berman SA. Markers of apoptosis: methods for elucidating the mechanism of apoptotic cell death from the nervous system. Biotechniques. 2002 Mar;32(3):648-50, 652, 654 passim.

Pan SY, Han YF, Carlier PR, Pang YP, Mak DH, Lam BY, Ko KM. Schisandrin B protects against tacrine- and bis(7)-tacrine-induced hepatotoxicity and enhances cognitive function in mice. Planta Med. 2002 Mar;68(3):217-20.

Ueda T, Nagata M, Monji A, Yoshida I, Tashiro N, Imoto T. Effect of sucrose on formation of the beta-amyloid fibrils and D-aspartic acids in Abeta 1-42. Biol Pharm Bull. 2002 Mar;25(3):375-8.

Prasher VP, Huxley A, Haque MS, Down syndrome Ageing Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study. Int J Geriatr Psychiatry. 2002 Mar;17(3):270-8.

Payne JL, Sheppard JM, Steinberg M, Warren A, Baker A, Steele C, Brandt J, Lyketsos CG. Incidence, prevalence, and outcomes of depression in residents of a long-term care facility with dementia. Int J Geriatr Psychiatry. 2002 Mar;17(3):247-53.

Shaji KS, Arun Kishore NR, Lal KP, Prince M. Revealing a hidden problem. An evaluation of a community dementia case-finding program from the Indian 10/66 dementia research network. Int J Geriatr Psychiatry. 2002 Mar;17(3):222-5.

Shigenobu K, Ikeda M, Fukuhara R, Maki N, Hokoishi K, Nebu A, Komori K, Tanabe H. Reducing the burden of caring for Alzheimer's disease through the amelioration of "delusions of theft" by drug therapy. Int J Geriatr Psychiatry. 2002 Mar;17(3):211-7.

Bassiony MM, Warren A, Rosenblatt A, Baker A, Steinberg M, Steele CD, Lyketsos CG. Isolated hallucinosis in Alzheimer's disease is associated with African-American race. Int J Geriatr Psychiatry. 2002 Mar;17(3):205-10.

Isella V, Melzi P, Grimaldi M, Iurlaro S, Piolti R, Ferrarese C, Frattola L, Appollonio I. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease. Mov Disord. 2002 Mar;17(2):366-71.

Levy G, Tang MX, Cote LJ, Louis ED, Alfaro B, Mejia H, Stern Y, Marder K. Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study. Mov Disord. 2002 Mar;17(2):250-7.

Krinsky-McHale SJ, Devenny DA, Silverman WP. Changes in explicit memory associated with early dementia in adults with Down's syndrome. J Intellect Disabil Res. 2002 Mar;46(Pt 3):198-208.

Matthews KL, Chen CP, Esiri MM, Keene J, Minger SL, Francis PT. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry. 2002 Mar 1;51(5):407-16.

Gard PR. The role of angiotensin II in cognition and behaviour. Eur J Pharmacol. 2002 Mar 1;438(1-2):1-14.

Bullock R, Connolly C. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it? Int J Geriatr Psychiatry. 2002 Mar;17(3):288-9.

Shepherd CE, McCann H, Thiel E, Halliday GM. Neurofilament-immunoreactive neurons in Alzheimer's disease and dementia with Lewy bodies. Neurobiol Dis. 2002 Mar;9(2):249-57.

Zhou Y, Zhang W, Easton R, Ray JW, Lampe P, Jiang Z, Brunkan AL, Goate A, Johnson EM, Wu JY. Presenilin-1 protects against neuronal apoptosis caused by its interacting protein PAG. Neurobiol Dis. 2002 Mar;9(2):126-38.

McKeel DW, Masliah E, Hansen LA, Morris JC. Commentary on "Synaptic Pathology in Prefrontal Cortex Is Present only with Severe Dementia in Alzheimer Disease" (JNEN 2001; 60;929-36). J Neuropathol Exp Neurol. 2002 Mar;61(3):295-6.

Thal DR, Ghebremedhin E, Rüb U, Yamaguchi H, Tredici KD, Braak H. Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2002 Mar;61(3):282-93.

Anderson SJ, Barker PE, Hadfield MG. Cytonectin expression in Alzheimer disease. J Neuropathol Exp Neurol. 2002 Mar;61(3):230-6.

Schneider B, Weber B, Maurer K, Frölich L. [Difficulties in the evaluation of depressive symptoms in patients with dementia] Psychiatr Prax. 2002 Mar;29(2):76-82.

Schmidt R, Lechner A, Petrovic K. Rivastigmine in outpatient services: experience of 114 neurologists in Austria. Int Clin Psychopharmacol. 2002 Mar;17(2):81-5.

Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, Hartmann T. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci. 2002 Mar 1;22(5):1679-89.